Representing Portola Pharmaceuticals, Inc. in protecting their cardiovascular drugs, Elinogrel and Betrixaban. Elinogrel was licensed for development and commercialization by Novartis for up to $500 million and Betrixaban is licensed to Merck for up to $420 million. 

Experience Center

Match our Experience to Your Needs

Experience Highlights

Internal investigation regarding potential Foreign Corrupt Practices Act violations
Internal investigation on behalf of a board of directors of a Fortune 500 company regarding potential Foreign Corrupt Practices Act more
Board of Supervisors of Louisiana State University et al. v. Smack Apparel Co.
Represented four major universities and The Collegiate Licensing Company (CLC) in a trade dress infringement case. In an attempt to avoid the more
Counselor for individual and his five franchises in a lawsuit regarding alleged violations of a non-competition covenant in the franchise agreement
Represented an individual and his five franchises, as plaintiffs, in a lawsuit regarding alleged violations of a non-competition covenant more
Preliminary injunction for real estate companies protecting their trademark
Obtained a preliminary injunction on behalf of three real estate companies, preventing the defendant from using our clients' names to describe its more